Jazz Pharmaceuticals: Relief Rally On 2026 Oxybate Franchise's Outlook
Source: SeekingAlpha
2026-02-26 08:19:46 ET
Jazz Pharmaceuticals overview
Looking at the market reaction to Jazz Pharmaceuticals' ( JAZZ ) Q4 2025 results and guidance for 2026, one has to think it is a relief rally since the quarterly results were just slightly better than expected and the 2026 revenue guidance range was below the Street consensus at the midpoint....
Read the full article on Seeking Alpha
For further details see:
Jazz Pharmaceuticals: Relief Rally On 2026 Oxybate Franchise's Outlook
Jazz Pharmaceuticals plc
NASDAQ: JAZZ
JAZZ Trading
2.12% G/L:
$183.77 Last:
228,273 Volume:
$179.88 Open:
JAZZ Latest News
February 24, 2026 04:05:00 pm
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
JAZZ Stock Data
$10,064,526,163
58,152,216
1.22%
231
N/A
Biotechnology & Life Sciences
Healthcare
IE
Dublin 4
